Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of the study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of daily subcutaneous administration of 5 μg/kg tbo-filgrastim in infants, children and adolescents with solid tumors without bone marrow involvement.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion:
Male or female infants, children and adolescents aged 1 month to <16 years.
Patients with solid tumors without bone marrow involvement, who are scheduled to receive myelosuppressive CTX.
Body weight ≥5 kg.
Patients must have an initial diagnosis and histologic proof of their malignancy. All enrolled subjects should have signed consent for a CTX regimen that is known to be myelotoxic, with counts expected to drop below the absolute neutrophil count (ANC) of 0.5 × 109/L for at least 3 days. These regimens would include at least one of the following:
ANC and platelet count: Patients must have an ANC >1 × 109/L and a platelet count >100 × 109/L to be eligible for therapy at the start of CTX.
Normal cardiac, renal, and hepatic function.
All subjects must have a life expectancy of 12 weeks or more.
Performance Status: Lansky performance score >60 (age 1 to <16 years).
Exclusion:
Bone marrow involvement.
Active myelogenous leukemia or history of myelogenous leukemia.
Previous treatment with colony-stimulating factors (granulocyte colony-stimulating factor [G-CSF], granulocyte-macrophage colony-stimulating factor, interleukin 11 [IL-11]) less than 6 weeks prior to study entry.
History of congenital neutropenia or cyclic neutropenia.
Pregnant or nursing female patients.
Fertile patients who do not agree to use highly reliable contraceptive measures Prior bone marrow or stem cell transplant, or prior radiation to ≥25% of bone marrow within the 4 weeks prior to the first tbo-filgrastim dose.
Ongoing active infection or history of infectious disease within 2 weeks prior to the screening visit.
Treatment with lithium at screening or planned during the study
Primary purpose
Allocation
Interventional model
Masking
50 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal